Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys

Masayuki Hashimoto,Noriyo Nagata,Tomoyuki Homma, Hiroki Maeda, Keiji Dohi,Naomi M. Seki,Ken Yoshihara,Naoko Iwata-Yoshikawa,Nozomi Shiwa-Sudo,Yusuke Sakai,Masayuki Shirakura,Noriko Kishida,Tomoko Arita, Yasushi Suzuki,Shinji Watanabe,Hideki Asanuma,Takuhiro Sonoyama,Tadaki Suzuki,Shinya Omoto,Hideki Hasegawa

Vaccine（2022）

引用 11|浏览9

暂无评分

摘要

•A novel SARS-CoV-2 recombinant spike (S)-protein vaccine S-268019-b was developed.•S-268019-b induced antibodies against S-protein and its receptor binding domain.•Neutralizing antibody was induced against SARS-CoV-2 and pseudovirus variants.•S-268019-b demonstrated protective efficacy against SARS-CoV-2 challenge.•S-268019-b was safe for use in cynomolgus macaques.

查看译文

关键词

Coronavirus disease 2019,Cynomolgus monkeys,Recombinant protein vaccine,S-268019-b,Severe acute respiratory syndrome coronavirus 2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要